期刊
ACTA TROPICA
卷 215, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.actatropica.2020.105806
关键词
Paromomycin; Drug susceptibility; Cutaneous leishmaniasis; Leishmania
资金
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2016/21171-6]
- UK Research and Innovation via the Global Challenges Research Fund under grant agreement 'A Global Network for Neglected Tropical Diseases' [MR/P027989/1]
- FAPESP [2018/03299-0, 2017/18488-4, 2020/01948-1]
Treatment of tegumentary leishmaniasis in Brazil is currently limited to a few drugs, highlighting the need for expansion of therapeutic options. Paromomycin, an aminoglycoside antibiotic already approved for visceral leishmaniasis, shows promising activity against clinical isolates of tegumentary leishmaniasis in Brazil.
Treatment of tegumentary leishmaniasis in Brazil is limited to pentavalent antimonial, amphotericin B and pentamidine. These drugs, administered parenterally, cause several side effects and have a varied clinical response, depending on the species of Leishmania. Urgent expansion of the therapeutic arsenal against the disease is therefore necessary. Pammomycin is an aminoglycoside antibiotic that has already been approved for the treatment of visceral leishmaniasis in Southeast Asia. Here, we provide an in vitro evaluation of the activity of paromomycin in fifteen clinical isolates from patients with tegumentary leishmaniasis at a reference center for the treatment of the disease. Furthermore, the in vitro susceptibility to this drug in reference strains of Leishmania species that are endemic in Brazil has also been evaluated. Among the clinical isolates, nine were typed as Leishmania (Viannia) braziliensis, five as L. (Leishmania) amazonensis and one as L. (V.) guyanensis. Although never exposed to paromomycin, we found variable susceptibility among these isolates and reference strains in promastigotes and intracellular amastigotes, with the drug being more active in the amastigote form of the parasite. This study provides a preclinical dataset that is useful for the evaluation of pammomycin in the treatment of tegumentary leishmaniasis caused by species that are endemic in Brazil.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据